[{"id":"beb45158-c589-4777-892d-6d101302161a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04595162","created_at":"2021-01-19T20:29:16.666Z","updated_at":"2025-02-25T14:59:25.170Z","phase":"Phase 1","brief_title":"A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL","source_id_and_acronym":"NCT04595162","lead_sponsor":"Peking University Third Hospital","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC019F"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/15/2021","start_date":" 03/15/2021","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2035","study_completion_date":" 12/15/2035","last_update_posted":"2020-10-20"}]